TY - JOUR T1 - Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1186/s40425-018-0391-1 VL - 6 IS - 1 SP - 102 AU - Maartje W. Rohaan AU - Joost H. van den Berg AU - Pia Kvistborg AU - John B. A. G. Haanen Y1 - 2018/12/01 UR - http://jitc.bmj.com/content/6/1/102.abstract N2 - The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over the world. Even in the era of targeted therapy and immune checkpoint inhibition, TIL therapy can be an additional and clinically relevant treatment line. This review provides an overview of the clinical experiences with TIL therapy thus far, including lymphodepleting regimens, the use of interleukin-2 (IL-2) and the associated toxicity. Characteristics of the TIL products and the antigen recognition pattern will be discussed, as well as the current and upcoming production strategies, including the selective expansion of specific fractions from the cell product. In addition, the future potential of TIL therapy in melanoma and other tumor types will be covered.Abbreviations:ACTAdoptive cell therapyAEAdverse eventb.i.d.Bis in dieC/TCancer/testisCCITCenter for Cancer Immune TherapyCDCluster of differentiationCDK4Cyclin-dependent kinase 4CRComplete remissionCTLA-4Cytotoxic T-lymphocyte-associated protein-4CXCRC-X-C chemokine receptorCyCyclophosphamidedDayDCDendritic cellDNADeoxyribonucleic acidFACSFluorescence-activated cell sortingFluFludarabineFoxP3Forkhead box PGMPGood manufacturing practiceGp100Glycoprotein 100GyGrayHDHigh-doseHLAHuman leukocyte antigenHPVHuman papillomavirushHouri.dIntradermali.v.IntravenousIFNInterferonILInterleukinIpiIpilimumabIUInternational unitkgKilogramLDLow-doseLDHLactate dehydrogenaseLN-144TIL production technology developed by Iovance BiotherapeuticsLPSLipopolysaccharideMART-1Melanoma antigen recognized by T cells 1maxMaximumMDMelanoma differentiationmgMilligramMHCMajor histocompatibility complexMIUMillion international unitsmRNAMessenger RNANANot availableNGFRNerve growth factor receptorNHSNational Health ServiceNIHNational Institutes of HealthNivoNivolumabNKINetherlands Cancer InstituteNMANon-myeloablativeOEOverexpressedORRObjective response rateOSOverall survivalPDProgressive diseasePD-1Programmed death protein-1PDL-1Programmed death ligand-1PDXPatient derived xenograftPembroPembrolizumabPFSProgression free survivalPRPartial responseqEveryRCTRandomized controlled trialREPRapid Expansion ProtocolRFSRelapse free survivals.c.Subcutaneoust.i.d.Ter in dieTBITotal body irradiationTCRT cell receptorTILTumor-infiltrating lymphocytesTNFTumor necrosis factorTregRegulatory T cellVemVemurafenibwWeekxTimesyrYear ER -